Brain 17 Vienna
PROFILE trials
ALK+ advanced NSCLC & brain metastases
PROFILE 1005
PROFILE 1007
Phase II
randomise
730 patients
158 patients
Crizotinib
Crizotinib
chemotherapy
888 patients
brain metastases
no brain metastases
613 patients
275 patients
Brain metastases in patients with ALK-positive NSCLC
Costa et al 2015, J Clin Oncol; 33 (17): 1881-1888
Made with FlippingBook - Online catalogs